@article{article, title  = {{A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial}},

 publisher = {{American Society of Hematology}},

 url = {{}},

 year = {{2013}},

 month = {{11}},

 author = {{Cook G and Williams CD and Cairns DA and Fletcher M and Cavenagh JD and Snowden JA and Parrish C and Ashcroft J and Yong KL and Cavet J and Hunter H et al}},

 doi = {{10.1182/blood.v122.21.765.765}},

 volume = {{122}},

 journal = {{Blood}},

 issue = {{21}},

 pages = {{765-765}},

 note = {{Accessed on 2024/12/22}}}